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Promoter hypermethylation, a widely studied epigenetic event known to inﬂuence gene expression levels, has been proposed as
a potential biomarker in multiple types of cancer. Clinical diagnostic biomarkers are needed for reliable prediction of bladder
cancer recurrence. In this paper, DNA promoter methylation of ﬁve C-terminal Ras-association family members (RASSF1A,
RASSF2A,RASSF4,RASSF5,andRASSF6)wasstudiedin64formalin-ﬁxedparaﬃn-embedded(FFPE)bladdercancerandnormal
adjacent tissues using methylation-speciﬁc high-resolution melting (MS-HRM) analysis. Results showed that 73% (30/41) of
transitional cell carcinoma, 100% (3/3) of squamous cell carcinoma, and 100% (4/4) of small cell carcinoma demonstrated
promoter methylation of the RASSF1A or RASSF2A gene, but only 6% (1/16) of normal tissues had promoter methylation
of RASSF genes. Testing positive for hypermethylation of RASSF1A or RASSF2A promoter provided 77% sensitivity and 94%
speciﬁcity for identiﬁcation of cancer tissues with an area under the curve of 0.854, suggesting that promoter methylation analysis
of RASSF1A and RASSF2A genes has potential for use as a recurrence biomarker for bladder cancer patients.
1.Introduction
In 2011, about 52,000 men and 17,000 women will be di-
agnosed with bladder cancer in the United States. Before a
normal cell transforms into a bladder cancer cell, a series of
molecular alterations are accumulated to initiate the process
of transformation. Although we do not fully understand the
mechanisms, DNA alterations including hypermethylation
and somatic mutation are commonly observed events in
humancancer.InarecentbladdercancerstudyFGFR3muta-
tion in combination with APC, RASSF1A,a n dSFRP2 meth-
ylation markers provided a sensitivity of 90% using tissue
samples and 62% using paired urine samples to identify the
presence of cancer with 100% speciﬁcity [1]. In nonsmall
cell lung cancer (NSCLC) and breast cancer, studies showed
that RASSF1A had diﬀerent frequencies of methylation de-
pending on histology [2, 3]. In nasopharyngeal carcinoma,
RASSF2A was frequently inactivated by its promoter methy-
lation and the methylation correlated with lymph node
metastasis [4]. The Ras-association family, also called RASSF
tumor suppressor genes, currently includes 10 members. All
of the RASSF proteins contain a Ras-association domain on
their C-terminus (RASSF 1–6)o rN - t e r m i n u s( RASSF 7–
10). Two important issues that are not previously addressed
by studies of RASSF gene methylation are (1) whether all
of the RASSF family members show aberrant methylation
in bladder cancer and (2) whether methylation pattern of
RASSF genes can be used as a diagnostic biomarker.
RASSF1A(Ras-associationdomainfamily1isoformA)is
the ﬁrst identiﬁed RASSF family member which is frequently
epigenetically inactivated in a wide range of cancer types. As
a tumor suppressor gene, RASSF1A regulates the activation
of cell death [5], cell cycle [6], and microtubule formation
[7]. The methylation signature of RASSF1A is thought to be
among the earliest cellular changes in tumorigenesis [8]. As a
potential tumor suppressor, RASSF2 plays a role in apoptosis
and cell cycle arrest and is frequently downregulated in lung
tumor cell lines by hypermethylation [9]. Although the 5 
CpG island of RASSF3 has been identiﬁed earlier, RASSF3
does not show methylation in glioma tumor cell lines [10].2 Molecular Biology International
RASSF4 i sb r o a d l ye x p r e s s e di nd i ﬀerent human tissues, but
its expression is down-regulated by promoter hypermethy-
lation in a majority of tumor cell lines and primary tumors
[11]. As a proapoptotic Ras eﬀector, RASSF5 (NORE1A)i s
frequently inactivated by promoter methylation in human
tumors like glioma tumor cell lines, colorectal tumors, and
lung cancer [12–15]. RASSF6 promotes apoptosis by cooper-
ating with activated K-Ras to induce cell death and inhibit
t h et u m o rc e l ls u r v i v a l[ 16]. A high frequency of RASSF6
methylation is present in leukaemia-related diseases [17]. It
appears that all of C-terminal RASSF family members have
hypermethylation-inducedgeneinactivationinvarioustypes
of cancer. While there is extensive literature on RASSF1A,
other RASSF family members have not been studied as
widely.
High-resolution melting (HRM) analysis is a new meth-
odology that monitors the melting behavior of PCR ampli-
cons by using DNA intercalating ﬂuorescent dye [18]. Origi-
nally the LCGreen was used to develop a closed-tube method
for genotyping and mutation scanning [19]. New high sen-
sitive dyes such as EVA Green and SYTO 9 can be used at
saturation concentration to monitor the denaturing process
of PCR amplicons. Compared to traditional methylation
speciﬁc PCR (MSP) method, HRM is a reliable and simple
method for DNA methylation detection [20, 21].
In this study, to examine diagnostic value of RASSF gene
methylation, we identiﬁed the methylation status of CpG
islands associated with C-terminal RASSF 1–6 in a group
of formalin ﬁxed paraﬃn embedded bladder cancer samples
using a methylation speciﬁc HRM assay.
2. Methods
2.1. Control and FFPE Tumor Samples. Universal methylated
and unmethylated DNA samples (Zymo Research Corp,
orange, CA) were used as 100% and 0% methylated control.
The methylated DNA was serially diluted in unmethylated
DNA to create standard dilutions of 0%, 10%, 50%, and
100% methylated DNA. The standard dilutions from 100%
to 0% were used to semiquantitatively measure promoter
methylation status of C-terminal RASSF genes in FFPE sam-
ples.
FFPE blocks from 48 bladder cancer patients were col-
lectedbythedepartmentofpathologyandtheHumanTissue
Resource Network at The Ohio State University. The study
was conducted in accordance with the Institutional Review
Boardguidelines.Weobtained16pairedtumorandmatched
normal adjacent tissues and 32 tumor tissues (35 males
and 13 females, male-to-female ratio 2.7:1; median age 67
years, range 28–90 years). Among these patients, 41 cases
were diagnosed with transitional cell carcinoma; 4 cases were
small cell carcinoma and 3 cases were squamous cell carci-
noma. Clinicopathologic and demographic characteristic of
bladder cancer samples are shown in Table 1.
2.2. DNA Extraction. DNA samples were extracted using
Recover All Total Nucleic Acid Isolation Kit (Life Technolo-
gies Corporation, Carlsbad, CA). Brieﬂy, 5–10mg samples
were sliced from paraﬃn blocks and deparaﬃnizated by
xylene at 50◦C, followed by 100% ethanol wash. The air-dry
tissue samples were digested by proteinase K for 24hrs in a
microtube shaking incubator set at 50◦C. The digested sam-
ples were mixed with appropriate volume of isolation addi-
tiveand100%ethanol.Afterpassingthemixturethroughthe
ﬁlter cartridge, the DNA and RNA were retained on the ﬁlter.
The RNA was removed by on-ﬁlter RNase digestion. The
DNA was puriﬁed by washing buﬀer and eluted with 95◦C
nuclease-free water.
2.3. Bisulﬁte Modiﬁcation. The FFPE DNA bisulﬁte modiﬁ-
cation was processed using EZ DNA Methylation Kit (Zymo
Research Corp, Orange, CA). The double-stranded DNA was
denatured in M-Dilution Buﬀer for 15 minutes at 37◦C, and
then CT Conversion Reagent was added to each sample.
The samples were incubated in the dark at 50◦Cf o r1 2
hours followed by 4◦C for 10 minutes. After mixing with M-
Binding Buﬀer, the samples were passed through a Zymo-
Spin IC Column. The DNA puriﬁcation and desulphona-
tion were performed on the column. Finally, the bisulﬁte-
modiﬁed DNA was eluted by M-Elution Buﬀer from column
matrix.
2.4. MS-HRM Primer Design. MS-HRM is based on PCR
ampliﬁcation of bisulﬁte modiﬁed genomic DNA with sub-
sequent HRM analysis of PCR amplicons. The primers were
designed to amplify both methylated and unmethylated
DNA. Because of DNA degradation in FFPE samples, the
sizes of amplicons were limited to 80–180bp. The free online
tool from MethPrimer (http://www.urogene.org/methprim-
er/index1.html) was used speciﬁcally for primer design in
this RASSF promoter methylation study. Primer sequences
and amplicon lengths are shown in Table 2.
2.5. High-Resolution Melting Analysis (HRM). PCR ampli-
ﬁcation and high-resolution melting analysis were carried
out sequentially on a CFX96 real-time PCR system (Bio-
rad, Hercules, CA). PCR was performed in a 20µLt o t a l
volume containing: 10µL 2X Type-it HRM PCR Master
Mix (QIAGEN, Hilden, Germany), 1µL 10 picomol/µLM S -
HRM primer, 8µL nuclease-free water, and 1µLb i s u l ﬁ t e
converted DNA (theoretical concentration 10ng/µL). The
ampliﬁcation consisted of 10min at 95◦C, followed by 40
cycles of 10s at 95◦C, 30s at annealing temperature and 10s
at 72◦C. High-resolution melting analysis were performed
at the temperature ramping from 70–95◦Cb y0 . 2 ◦C/s and
ﬂorescence acquisition was set per manufacturer’s recom-
mendation.
2.6.StatisticalAnalysis. Methylationwasclassiﬁedaspositive
ifatleast10%methylationwasmeasured.Thechi-squaretest
was used to examine the signiﬁcant diﬀerences of methyla-
tion depending on histology and staging (P ≤ 0.05). To eval-
uate sensitivity and speciﬁcity of methylation as a predictive
marker receiver operating characteristic (ROC) analysis was
used.Molecular Biology International 3
Table 1: Patient demographic information.
Study populations
Total (N = 64) B l a d d e rc a n c e rt i s s u e
specimen (n = 48)
Matched bladder cancer and
normal adjacent tissues (n = 16)
Age (years): mean (range) 68 (28–90) 67 (28–90) 69 (53–90)
Gender
Male 35 35 12
Female 13 13 4
Histologic cell type
Transitional cell carcinoma 41 41 12
S m a l lc e l lc a r c i n o m a 4 4 1
Squamous cell carcinoma 3 3 3
Ts t a g e
T1 9 9 2
T2 11 11 3
T3 18 18 8
T4 6 6 1
Tx 4 4 4
Ns t a g e
N0 27 27 9
N1 8 8 2
N2 8 8 3
Nx 5 5 2
3. Results andDiscussion
To generate a proﬁle of C-terminal RASSF gene epigenetic
changes in bladder cancer, 64 bladder FFPE tissue samples
were examined by methylation-speciﬁc HRM assay. The
C-terminal RASSF family members (RASSF1A, RASSF2A,
RASSF4, RASSF5,a n dRASSF6) were analyzed in this study.
In the UCSC Genome Browser, we found a CpG island in
the RASSF3 promoter region. However, due to the dense CG
dinucleotides on the CpG island of the identiﬁed RASSF3
promoter, no appropriate HRM primers could be designed
for this gene.
3.1. Quality Assessment of Methylation-Speciﬁc HRM Assay.
HRM assay uses double-stranded DNA binding dyes and re-
quires less PCR optimization than other methods. The prin-
ciple of HRM depends on recording the melting proﬁle of
double-stranded DNA samples. As double-stranded DNA is
denatured, the ﬂuorescence signal from dye bound to
double-stranded DNA decreases. The melting proﬁle is
related to amplicon length, DNA sequence and GC content.
The high-resolution melting requires smaller temperature
increase steps (<0.5◦C/s) between each ﬂuorescence reading,
which can provide detailed information of amplicon melting
behavior.
MS-HRM is a semi-quantitative method for rapidly
assessing the presence of DNA methylation. The standard
curve of methylation was used to conﬁrm the RASSF gene
methylation. The bisulﬁte-modiﬁed fully methylated DNA
was diluted in bisulﬁte-modiﬁed fully unmethylated DNA
to obtain a series of methylation percentage: 0%, 10%,
6000
5000
4000
3000
74 76 78 80 82 84
Melt curve
R
F
U
Temperature (◦C)
50% M 100% M
10% M
50% UM
Figure 1: Standard curve constructed for RASSF promoter methy-
lation. The dilutions of methylated DNA in unmethylated DNA are
as follows: 0% methylation, 10% methylation, 50% methylation,
and 100% methylation. Using Meth Primer software, a pair of
primerswasdesignedtoamplifybothmethylatedandunmethylated
sequences after bisulﬁte conversion. The melting curves of 0% and
100% methylation indicate melting temperature of unmethylated
sequence (76.6◦C )a n dm e t h y l a t e ds e q u e n c e( 8 1 ◦C).
50%, and 100% methylation. Only samples containing more
than 10% methylation were counted as methylated samples.
The standard curve of RASSF2A methylation is shown in
Figure 1.
3.2. RASSF Family Member Methylation Proﬁle in Tumor
and Normal Adjacent Tissue Samples. Promoter methylation
was analyzed in tumor and normal adjacent tissues from 164 Molecular Biology International
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Figure 2: RASSF1A and RASSF2A methylation proﬁles of tumor
and normal adjacent tissues. 71% (34/48) of tumor samples had
RASSF1A promoter methylation, and 8% (4/48) had RASSF2A
promotermethylation.NoRASSF4,RASSF5,andRASSF6 promoter
methylation were detected.
cases using MS-HRM [22]. 56% (9/16) of tumor samples
were found to have RASSF1A promoter methylation, and
25% (4/16) of tumor samples showed RASSF2A promoter
methylation, while only 6% (1/16) of the normal adjacent
tissue samples showed RASSF1A promoter methylation and
none of normal adjacent tissue samples showed RASSF2A
methylation. RASSF 4, 5, and 6 were not found to be meth-
ylated in either tumor or normal adjacent tissues. Figure 2
demonstrates that tumor and normal adjacent tissue showed
diﬀerent RASSF1A and RASSF2A methylation proﬁles.
Among the 48 patients with bladder cancer, RASSF1A
promoter methylation alone had 71% sensitivity and 94%
speciﬁcity and an area under the curve (AUC) of 0.823 to
correctly identify bladder cancer tissue whereas RASSF1A
and RASSF2A together had 77% sensitivity and 94% speci-
ﬁcity and AUC of 0.854. RASSF1A and RASSF2A promoter
methylation did discriminate bladder cancer tissue from
normal adjacent tissue (P<0.0001).
3.3. RASSF1A and RASSF2A Methylation Proﬁle in Diﬀerent
Histological Samples. Patient characteristics are summarized
in Table 1. 41 patients had tumors with transitional cell
carcinoma features 4 with small cell carcinoma, and 3 with
squamous cell carcinoma. RASSF1A w a sm e t h y l a t e di n6 8 %
(28/41) and RASSF2A in 7% (3/41) of transitional cell
carcinoma samples. Only one sample had methylation of
both the RASSF1A and RASSF2A promoters. RASSF1A was
methylated in 100% (4/4) and RASSF2A in 0% (0/4) of
s m a l lc e l lc a r c i n o m a .RASSF1A was methylated in 67% (2/3)
and RASSF2A in 33% (1/3) of squamous cell carcinoma
(Figure 3). The frequency of RASSF1 and RASSF2 promoter
methylation together showed no signiﬁcant diﬀerence with
histology in our study (P = 0.295).
ThereasonsthatleadtoaberrantCpGislandmethylation
of RASSF1A and RASSF2A in transitional cell carcinoma,
RASSF1A methylation
RASSF2A methylation
RASSF1A or RASSF2A
methylation
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Figure 3: RASSF1A and RASSF2A methylation proﬁles of diﬀerent
histology. RASSF1A was methylated in 68% (28/41) of transitional
cell carcinoma samples, in 100% (4/4) of small cell carcinoma and
in67%(2/3)ofsquamouscellcarcinoma.RASSF2Awasmethylated
in 7% (3/41) of transitional cell carcinoma samples, in 0% (0/4) of
small cell carcinoma, and in 33% (1/3) of squamous cell carcinoma.
small cell carcinoma, and squamous cell carcinoma of
the bladder are not well understood. Recent data by Li
et al. investigating nonsmall cell lung cancer showed that
RASSF1A promoter region CpG islands were methylated in
55% of adenocarcinomas, 25% of large cell carcinomas, and
25% of squamous cell carcinomas [3]. This study indicates
that promoter methylation of RASSF gene family members
might be dependent on histology in nonsmall cell lung
cancer.
3.4. RASSF1A and RASSF2A Methylation Proﬁle at Diﬀerent
TS t a g e s . 60 malignant bladder tumor and normal adjacent
tissue samples from patients with diﬀerent T stages (16
normal adjacent tissue samples, 9 stage T1, 11 stage T2,
18 stage T3, and 6 stage T4) were analyzed to detect the
RASSF promoter methylation changes of bladder cancer
patients. Methylated RASSF1A promoters were only found
in 6% (1/16) of normal adjacent tissues. The percentage
of promoter methylation positive patients increased with T
stage,being lowerinT1tumorsandhigherwithhigherstage.
The percentage of samples with methylated RASSF1A genes
was 55% (5/9) in stage T1, 73% (8/11) in stage T2, 78%
(14/18) in stage T3, and 83% (5/6) in specimens from T4
tumors (Figure 4). The frequency of RASSF1 and RASSF2
promoter methylation was not associated with T stage (P =
0.363). Due to lack of samples with RASSF2A methylation,
no association between RASSF2A methylation and T stage
was identiﬁed in the current data set. Similar results were
found in a recent lung cancer study [23]. The RASSF2A6 Molecular Biology International
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Figure 4: RASSF1A and RASSF2A methylation proﬁles in diﬀerent
Ts t a g e .RASSF1A was only 6% (1/16) in normal adjacent tissues,
but percentage of tumor samples with methylated RASSF1A genes
had a range of 55%−83% from T1 to T4 stage. The RASSF2A
promoter had a low level (0–18%) at diﬀerent T stages.
promoter methylation was found at low levels (0–18%) at
diﬀerent T stages.
3.5. RASSF1A and RASSF2A Methylation Proﬁle at Diﬀerent
NS t a g e s .We examined methylation status of RASSF1A
and RASSF2A in 27 bladder tumor samples with stage N0,
8 samples with stage N1, and 8 samples with stage N2.
Percentage of RASSF1Apromotermethylationhadarangeof
50–87.5% in tissues from patients with diﬀerent lymph node
metastasis stage. The percentage of samples with methylated
RASSF2A was 11% (3/27) for stage N0, and 6% (1/16) for
stage N1/2 (Figure 5). Based on the result of chi-square test,
there is no signiﬁcant diﬀerence between the frequency of
RASSF1 and RASSF2 promoter methylation in lymph node
positive and negative patients.
In nasopharyngeal carcinoma, aberrant methylation of
RASSF2A promotor was found to be associated with lymph
node metastasis [24]. Although both RASSF1A and RASSF2
protein can function as a negative eﬀector of Ras protein in
tumor formation, RASSF2A and RASSF1A have apparently
diﬀerent functions in diﬀerent type of tumors.
3.6. RASSF4, RASSF5, and RASSF5 Methylation. RASSF1-6
share a variable N-terminal sequence followed by a Ras-asso-
ciation domain [25]. The HRM analysis showed no detecta-
ble promoter methylation of RASSF4, RASSF5 and RASSF6
in bladder cancer and normal adjacent tissue samples.
4. Discussion
DNA methylation and histone modiﬁcation are widely stud-
ied epigenetic events. Promoter hypermethylation has been
proposed as a potential diagnostic or prognostic biomarker
in various cancers. Recent research showed that urine is
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Figure 5: RASSF1A and RASSF2A methylation proﬁles in diﬀerent
N stages. Percentage of RASSF1A methylation had a range of 50–
87.5% in diﬀerent N stage, and percentage of RASSF2A had range
of 0%−11%. Aberrant methylation of RASSF1A and RASSF2A
promotor showed no relationship to lymph node metastasis.
potentially useful for bladder cancer screening [26, 27].
Methylation status of certain genes identiﬁed in urine sam-
ples showed higher sensitivity than the conventional urine
cytology method. These studies indicated that detection of
promoter methylation in urine specimen could potentially
provide a simple, noninvasive, and suﬃciently sensitive
method for bladder cancer screening in the future.
In our study, a new methodology, methylation-speciﬁc-
high resolution melting analysis was used to examine the
melting behavior of methylated or unmethylated RASSF
gene amplicons. This provides a simple and reproducible
method for promoter methylation assessment. We studied
DNA promoter methylation of ﬁve RASSF family members
(RASSF1A, RASSF2A, RASSF4, RASSF5, and RASSF6)i n
FFPE bladder cancer tissues and normal adjacent tissues.
We identiﬁed distinctive RASSF1A and RASSF2A gene
promoter methylation proﬁles that diﬀerentiate between
bladder cancer and normal adjacent tissue samples. Using
RASSF1AandRASSF2Agenestogethershowedanacceptable
sensitivity (77%) and high speciﬁcity (94%) identifying
bladder cancer tissues. Previous studies have identiﬁed
RASSF1A promoter methylation as a potentially useful urine
biomarkerforthepresenceofinvasivebladdercancer[26,28,
29]. We now show that the addition of RASSF2A promoter
methylation analysis can improve the sensitivity potentially
without compromising speciﬁcity. There was no signiﬁcant
correlation of RASSF1A methylation with histology and N
stage. As discussed by Serizawa [1], results also showed that
FGFR3 mutation in bladder cancer when combined with
methylationmarkers(APC,RASSF1AandSFRP2)provideda
sensitivityof90%toidentifybladdertumors.Itremainstobe
shown if the addition of an RASSF2A promoter methylation
assay to the previously published urine biomarker assay
can indeed improve sensitivity when using urine samples.
Limitations of the study include small sample size or lackMolecular Biology International 7
of a validation data and sample set. In addition we did not
havesuﬃcientdatatoanalyzeifRASSF genefamilypromoter
methylation could predict the recurrence of bladder cancer.
Methylation analysis of both RASSF1A and RASSF2A
genes appeared to increase the sensitivity of discriminat-
ing cancer from normal adjacent tissue. The addition of
RASSF2A methylation analysis to recent bladder cancer bio-
marker signatures has the potential to further increase sen-
sitivity for bladder cancer diagnosis. RASSF1A and RASSF2A
promoter methylation analysis could be useful as a biomark-
er to detect the presence of bladder cancer recurrence.
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